Salivary Gland Procedures DRG Reimbursement Guide

DRG 139 addresses inpatient admissions for salivary gland procedures such as excision, drainage, and gland removal, encompassing both benign and malignant indications. This Diagnosis-Related Group matters for inpatient reimbursement because it groups clinically similar surgical cases to determine Medicare prospective payments that reflect expected resource use.

DRG 139 Overview

DRG 139 covers inpatient admissions for salivary gland procedures, including excision, drainage, and partial or total gland removal for benign and malignant conditions. This Diagnosis-Related Group is relevant when these procedures are the principal reason for hospitalization and may involve varying complexity based on patient comorbidities and surgical approach. It matters for Medicare payment because it groups cases with similar clinical resource needs to determine prospective payment rates under the inpatient prospective payment system. Accurate coding of procedures and any Complication or Comorbidity or Major Complication or Comorbidity is essential to assign the correct Diagnosis-Related Group and resulting payment.

Acute perioperative management and complication reduction trials: studies in this area evaluate interventions to reduce intraoperative bleeding, facial nerve injury, surgical site infections, or postoperative salivary fistula following parotidectomy, submandibular gland excision, or sialendoscopy. Typical patient populations are adults undergoing planned or urgent salivary gland surgery for obstructive sialadenitis, neoplasms (benign or malignant), or traumatic injury; trials may test hemostatic techniques, nerve-monitoring protocols, or perioperative antibiotic and steroid strategies. These trials matter to surgeons, hospital administrators, and payers because reducing immediate complications shortens length of stay, lowers readmission risk, and decreases high-cost downstream resource use.
Comparative effectiveness and surgical technique trials: randomized or observational studies compare different operative approaches (e.g., superficial versus total parotidectomy, extracapsular dissection versus formal resection, endoscopic sialendoscopy versus open gland excision) and adjuncts such as intraoperative nerve monitoring or reconstructive flaps. These studies focus on patient-centered outcomes including facial nerve function, recurrence rates for benign and malignant tumors, functional saliva production, aesthetic results, and procedure-related costs in populations stratified by tumor type, gland involved, and comorbidity burden. Results inform clinical guidelines and payer coverage decisions by identifying techniques that optimize long-term outcomes and cost-effectiveness for distinct subgroups within the DRG.
Post-discharge outcomes, rehabilitation, and health-services research: prospective cohort studies and pragmatic trials assess long-term functional recovery, quality of life, chronic xerostomia management, surveillance protocols for malignancy, and patterns of outpatient care and readmission after discharge for salivary gland procedures. These investigations enroll patients after hospital discharge to study rehabilitation needs (speech/swallow therapy), chronic pain or dry mouth interventions, and the impact of follow-up intensity on recurrence detection and costs. Findings are relevant to providers and payers because they guide resource allocation for outpatient services, surveillance intervals, and supportive care that can reduce costly complications and improve patient-reported outcomes associated with this DRG.

Acute perioperative management and complication reduction trials: studies in this area evaluate interventions to reduce intraoperative bleeding, facial nerve injury, surgical site infections, or postoperative salivary fistula following parotidectomy, submandibular gland excision, or sialendoscopy. Typical patient populations are adults undergoing planned or urgent salivary gland surgery for obstructive sialadenitis, neoplasms (benign or malignant), or traumatic injury; trials may test hemostatic techniques, nerve-monitoring protocols, or perioperative antibiotic and steroid strategies. These trials matter to surgeons, hospital administrators, and payers because reducing immediate complications shortens length of stay, lowers readmission risk, and decreases high-cost downstream resource use.
Comparative effectiveness and surgical technique trials: randomized or observational studies compare different operative approaches (e.g., superficial versus total parotidectomy, extracapsular dissection versus formal resection, endoscopic sialendoscopy versus open gland excision) and adjuncts such as intraoperative nerve monitoring or reconstructive flaps. These studies focus on patient-centered outcomes including facial nerve function, recurrence rates for benign and malignant tumors, functional saliva production, aesthetic results, and procedure-related costs in populations stratified by tumor type, gland involved, and comorbidity burden. Results inform clinical guidelines and payer coverage decisions by identifying techniques that optimize long-term outcomes and cost-effectiveness for distinct subgroups within the DRG.
Post-discharge outcomes, rehabilitation, and health-services research: prospective cohort studies and pragmatic trials assess long-term functional recovery, quality of life, chronic xerostomia management, surveillance protocols for malignancy, and patterns of outpatient care and readmission after discharge for salivary gland procedures. These investigations enroll patients after hospital discharge to study rehabilitation needs (speech/swallow therapy), chronic pain or dry mouth interventions, and the impact of follow-up intensity on recurrence detection and costs. Findings are relevant to providers and payers because they guide resource allocation for outpatient services, surveillance intervals, and supportive care that can reduce costly complications and improve patient-reported outcomes associated with this DRG.

OpenPayer

Summary & Overview

Salivary Gland Procedures: Inpatient Reimbursement Overview

DRG 139 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes